TetraKit Technologies is proud to announce that our lead compound, DualFAPi, a fibroblast activation protein (FAP)-targeted dimer designed to prolong tumor residence, has been selected as one of three candidates for clinical evaluation under the Accelerate.EU initiative. This €16 million project, funded by the Institute for Health Innovation (IHI), brings together 17 leading institutions from 9 European countries to advance the development of radiotheranostics and alpha particle cancer therapies.

The Accelerate.EU initiative aims to establish a comprehensive value chain for astatine-211 (²¹¹At), a highly promising alpha particle emitter for targeted cancer therapy. Through this collaborative effort, TetraKit Technologies, alongside consortium partners including IBA, the University of Copenhagen, Rigshospitalet, Institut Jules Bordet, and others, is working to develop innovative theranostic agents that integrate tumor-targeted radiation with advanced imaging modalities.

Within the consortium, TetraKit Technologies will:

1) Enhance its expertise in ²¹¹At radiolabeling and theranostic radiopharmaceutical development

2) Lead the advancement of novel compounds such as ²¹¹At-DualFAPi and ¹²³I-DualFAPi, which are progressing towards Phase 1 clinical trials. They target aggressive cancers including triple-negative breast cancer (TNBC)

3) Strengthen its position as a frontrunner in radiopharmaceutical innovation through collaboration with premier European academic and industrial partners

This significant milestone highlights the commitment of all partners involved in the Accelerate.EU consortium to improve cancer treatment options and outcomes. TetraKit Technologies acknowledges the vital coordination efforts of IBA and Institut Jules Bordet, as well as the support provided by IHI.

We remain dedicated to advancing this transformative project and to contributing to the development of novel, effective cancer therapies for patients with unmet medical needs.